ABSTRACT

Objectives: Non-reconstituted, hexavalent vaccines (HV-NRs) can facilitate clinical practice by shortening vaccine preparation and administration time and by reducing the risk of vaccination errors compared to combination vaccines requiring reconstitution. The aim of this study was to determine the budget impact of introducing an HV-NR into the United Kingdom’s (UK) pediatric immunization program, which currently uses a hexavalent vaccine requiring reconstitution (HV-R).

Methods: Abudget impact model covering a 10-year time horizon was developed. The target population constituted closed UK birth cohorts from 2020 to 2029. Total direct costs from the payer’s perspective consisted of four main categories: vaccine acquisition and management, healthcare provider’s service provision, (non-)contaminated needle-stick and sharps injury (NSI), and non-NSI vaccination error costs. The net budget impact was calculated by comparing the costs in two different market share scenarios.

Results: The use of HV-NR instead of HV-R was estimated to save £9,079,927 over a 10-year time horizon (i.e. £907,993 per year). Assuming all other vaccine criteria are equivalent the budget impact was most sensitive to changes in time spent by the healthcare provider and management costs.

Conclusion: Results suggest, introducing an HV-NR into the UK’s pediatric immunization program is potentially cost saving for the healthcare system.

摘要

目标：与需要重组的联合疫苗相比，非重组六价疫苗（HV-NRs）可通过缩短疫苗的制备和给药时间以及减少接种错误的风险来促进临床实践。这项研究的目的是确定将HV-NR引入英国（UK）的儿童免疫计划的预算影响，该计划目前使用需要重建的六价疫苗（HV-R）。

方法：建立了涵盖10年时间范围的预算影响模型。目标人群是2020年至2029年英国封闭式出生队列。从付款人的角度来看，总直接费用包括四个主要类别：疫苗购买和管理，医疗服务提供者的服务，（未受污染的）针刺和锐器伤（NSI） ，以及非NSI疫苗接种错误费用。通过比较两种不同市场份额情况下的成本来计算预算净影响。

结果：在10年的时间范围内，使用HV-NR代替HV-R估计可节省9,079,927英镑（即每年907,993英镑）。假设所有其他疫苗标准都相同，则预算影响对医疗保健提供者花费的时间变化和管理成本最为敏感。

结论：结果表明，将HV-NR引入英国的儿科免疫计划可能会节省医疗保健系统的成本。